PBI-203

N/A

Report date: 2024/11/15 16:10:27

Base Information

Drug NamePBI-203

Drug Alias NamePBI-203

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionVascular endothelial growth factor inhibitorsProgrammed death-ligand 1 blockers

TargetsVascular endothelial growth factorProgrammed death-ligand 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesProtheragen Inc

China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A